Application of miR-193a/WT1/PODXL axis to estimate risk and prognosis of idiopathic membranous nephropathy.
Application of miR-193a/WT1/PODXL axis to estimate risk and prognosis of idiopathic membranous nephropathy. Ren Fail. 2019 Nov;41(1):704-717 Authors: Zhang W, Ren Y, Li J Abstract Background: This investigation was managed to explore whether miR-193a in combination with two podocytes, namely, Wilms tumor type 1 (WT1) and podocalyxin (PODXL), were feasible in estimating onset and prognosis of idiopathic membranous nephropathy (IMN). Methods: We recruited a total of 189 healthy controls and 364 IMN patients, whose urine samples were prepared to measure the expression of miR-193a and PODXL. Meanwhile, renal tissues collected from above-mentioned IMN patients (n = 364) and renal cell carcinoma patients (n = 189) were arranged to determine the expression of WT1. Ultimately, receiver operating characteristic curves were constructed to appraise the performance of miR-193a, WT1, and PODXL in predicting renal survival of IMN patients. Results: The IMN patients were measured with up-regulated miR-193a expression and down-regulated WT1/PODXL expression, when compared with healthy controls (p 3.79 g/24 h)/serum creatinine (>174.63 μmol/L), and declined GFR (≤68.13 mL/min/1.73 m2) were implicated as prominent biomarkers for the poor renal survival of IMN patients (all p
Publication date: Available online 25 February 2020Source: Actas Urológicas Españolas (English Edition)Author(s): G. del Pozo Jiménez, F. Herranz Amo, J.A. Arranz Arija, E. Rodríguez Fernández, D. Subirá Ríos, E. Lledó García, G. Bueno Chomón, M.J. Cancho Gil, J. Carballido Rodríguez, C. Hernández Fernández
Publication date: Available online 25 February 2020Source: The American Journal of SurgeryAuthor(s): Kristen E. Limbach, SuEllen J. Pommier, Elizabeth Dewey, Enrique Leon, Rodney F. Pommier
Publication date: March 2020Source: Human Pathology: Case Reports, Volume 19Author(s): Van Chu Nguyen, Thi Huyen Phung, Tien Quang Nguyen, Phuong Hoa Nguyen Thi
Publication date: Available online 25 February 2020Source: Gynecologic Oncology ReportsAuthor(s): Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin
Authors: Medeiros MC, Rocha N, Bandeira E, Dantas I, Chaves C, Oliveira M, Bandeira F Abstract Sclerostin (Scl) is an osteoblast-inhibiting glycoprotein that is secreted mainly by osteocytes and is regulated by hormonal changes and skeletal loading. Decreased physical function and high serum Scl concentrations have been reported in chronic renal failure patients but little is known to date about the differences between diabetic and non-diabetic patients on hemodialysis who are susceptible to both sarcopenia and bone fragility. Objective.To determine the prevalence of sarcopenia and its association with serum Scl co...
CONCLUSIONS: In cases of BCCs with thickness of ≤1 mm, there was a high correlation (r=0.870) of the tumor spread depth between micromorphological measurements and the results obtained using a 75 MHz transducer and in cases of BCCs with thickness of>1 mm, a very high correlation (r=0.951) of the tumor spread depth was observed between histomorphometry and30 MHz transducer measurements. PMID: 32096785 [PubMed - as supplied by publisher]
Publication date: Available online 25 February 2020Source: Clinica Chimica ActaAuthor(s): Juan Zhou, Xinxin Zhang, Huifang Tang, Jia Yu, Xuyu Zu, Zhizhong Xie, Xiaoyan Yang, Juan Hu, Fang Tan, Qing Li, Xiaoyong Lei
Conditions: Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 Interventions: Biological: Necitumumab; Drug: Osimertinib; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Biological: Trastuzumab Sponsors: Jonsson Comprehensive Cancer&...
Condition: Recessive Dystrophic Epidermolysis Bullosa Intervention: Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting
Conditions: Ectomesenchymoma; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medull oblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectode...